Valeo Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VPHIF research report →
About the company
Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to sourcing, licensing, and selling a variety of medicinal products, with a primary emphasis on respiratory, specialized, and hospital-grade generic drugs. Its extensive product lineup features prominent asthma medications like Enerzair Breezhaler (a triple-combination LABA/LAMA/ICS) and Atectura Breezhaler (a dual-combination LABA/ICS).
- CEO
- Kyle Steiger
- IPO
- 2020
- Employees
- 70
- HQ
- Kirkland, QC, CA
Price Chart
- Market Cap
- $9.87K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -5.06
- Div Yield
- 0.00%
- Gross Margin
- 24.26%
- Op Margin
- -31.96%
- Net Margin
- -51.58%
- ROE
- 95.58%
- ROIC
- -67.29%
- Revenue
- $53.91M · 94.31%
- Net Income
- $-27,808,000 · -8.01%
- EPS
- $-0.32 · 0.00%
- Op Income
- $-17,228,000
- FCF YoY
- 39.97%
- 52W High
- $0.12
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.80
- Avg Volume
- 39.36K
Get TickerSpark's AI analysis on VPHIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VPHIF coverage
Recent articles, reports, and earnings notes.
No research on VPHIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VPHIF report →Similar companies
Peers in the same neighborhood.